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Background. The twelve-lead electrocardiogram (ECG) has become an essential tool for the 2 
diagnosis, risk stratification, and management of patients with acute coronary syndromes (ACS). 3 
However, several areas of residual controversies or gaps in evidence exist. Among them, P-wave 4 
abnormalities identifying atrial ischemia/infarction are largely neglected in clinical practice, and their 5 
diagnostic and prognostic implications remain elusive; the value of ECG to identify the culprit lesion 6 
has been investigated, but validated criteria indicating the presence of coronary occlusion in patients 7 
without ST-elevation are lacking; finally, which criteria among the multiple proposed, better define 8 
pathological Q-waves or success of revascularisation deserve further investigations  9 
Methods. The Minimizing Adverse hemorrhagic events via TRansradial access site and systemic 10 
Implementation of AngioX (MATRIX) trial was designed to test the impact of bleeding avoidance 11 
strategies on ischemic and bleeding outcomes across the whole spectrum of patients with ACS 12 
receiving invasive management. The ECG-MATRIX is a pre-specified sub-study of the MATRIX 13 
programme which aims at analyzing the clinical value of ECG metrics in 4,516 ACS patients (with 14 
and without ST-segment elevation in 2,212 and 2,304 cases, respectively) with matched pre and post-15 
treatment ECGs.  16 
Conclusions. This study represents a unique opportunity to further investigate the role of ECGs in the 17 
diagnosis and risk stratification of ACS patients with or without ST-segment deviation, as well as to 18 
assess whether the radial approach and bivalirudin may affect post-treatment ECG metrics and patterns 19 
in a large contemporary ACS population. 20 
 21 
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The twelve-lead standard trans-thoracic electrocardiogram (ECG) remains a fundamental instrument 2 
for the diagnosis, risk stratification, and treatment of patients with suspected or confirmed acute 3 
coronary syndrome (ACS)[1–3]. Matched pre and post-treatment ECGs analysis provides additional 4 
information on the success (or failure) of epicardial flow restoration, as well as microvascular 5 
reperfusion, and risk stratification for short- and long-term outcomes[4–6]. Numerous studies have 6 
investigated the diagnostic and prognostic role of ECG in patients with ACS undergoing invasive 7 
management (supplementary appendix, Table S1)[4–12]. However, several issues remain unclear. 8 
Among them, P-wave abnormalities identifying atrial ischemia/infarction are largely neglected in 9 
clinical practice, as their diagnostic and prognostic implications remain elusive[13–17]. Numerous 10 
studies have assessed the value of specific ECG patterns/algorithms to identify culprit lesion, but they 11 
suffer from multiple limitations, and their usefulness needs to be reassessed[18–25]. Validated criteria 12 
indicating the presence of coronary occlusion in patients without ST-elevation are lacking and would 13 
carry major implications for practice[26–30]. Further questions regarding the impact of access site 14 
and/or antithrombotic regimens on atrial and ventricular ischemia assessed by ECG analysis remain 15 
poorly investigated and would deserve further attention.  16 
The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic 17 
Implementation of Angiox (MATRIX) was a programme of three nested, randomised, multicentre 18 
trials[31–34] assessing the comparative safety and effectiveness of radial versus femoral access and 19 
bivalirudin versus unfractionated heparin (with optional glycoprotein IIb/IIIa inhibitors) in 8,404 20 
patients with ACS (with or without ST-segment deviation) undergoing invasive management. Within 21 
the programme, an electrocardiography sub-study (ECG-MATRIX) was pre-specified in the trial 22 
protocol (available online at 23 
https://nejm.org/doi/full/10.1056/NEJMoa1507854#article_supplementary_material)[32] and designed 24 
in accordance with previously proposed criteria for conducting an ECG sub-study nested within 25 
prospective trials in patients with coronary artery disease[35]. 26 
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In this paper, we intend to highlight the remaining areas of controversies surrounding the role of the 1 
ECG in the management of ACS patients coupled with the rationale for and design of the ECG-2 
MATRIX. 3 
 4 
Role of P-wave morphology for the diagnosis of atrial infarction and prediction of 5 
supraventricular arrhythmias and outcomes  6 
Since its first description in 1925[36], atrial infarction remains an elusive entity and a potentially 7 
unrecognized cause of atrial dysfunction and supraventricular arrhythmias[37,38]. Major concepts 8 
about the clinical presentation of the disease have been previously reviewed[12,14](search strategy 9 
detailed in supplementary appendix). Atrial infarction can occur in up to 30% of patients with 10 
concomitant ventricular infarction[16,17], while it has been rarely reported as isolated 11 
findings[12,39,40]. The majority of atrial infarctions occur as a consequence of atherosclerotic 12 
coronary disease, as the result of occlusion of atrial coronary branches, and are either thrombotic or 13 
percutaneous coronary intervention (PCI) related. As atrial branches typically arise from proximal 14 
right and/or left circumflex coronary arteries, their involvement is generally associated with coronary 15 
lesions jeopardizing a large ventricular mass[12,37]. Accidental atrial branch occlusion during elective 16 
PCI is a neglected but relatively frequent cause of ischemic atrial damage[37], associated with peri-17 
procedural myocardial infarction (MI), atrial arrhythmias, and intra-atrial conduction delay[37]. 18 
Although challenging, the diagnosis of atrial ischemia/infarction can be made via the assessment of 19 
suspected ECG alterations, including abnormal P-wave morphology (i.e., notched shape, ‘M’ or ‘W’ 20 
pattern), prolonged P-wave duration (i.e., inter-atrial block), PR-segment deviation, or new-onset atrial 21 
arrhythmias (i.e., atrial premature beats, atrial fibrillation)[12,13,15,41,42]. Moreover, the ECG 22 
confers the possibility of defining atrial injury localization, showing a relatively high incidence of 23 
right (81-98%) as compared to left (2-19%) or bi-atrial (19-24%) involvement[14,15]. To date, the 24 
definition remains the main issue in diagnosing atrial infarction at ECG because of the lack of 25 
universally accepted criteria. Burch suggested that any PR-deviation (even a fraction of a millimeter) 26 
should be considered as potentially suspicious for atrial infarction, although this approach may lack 27 
adequate accuracy[14,42]. The criteria currently used, were proposed by Liu et al. in 1961 and based 28 
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on a small case series (Figure 1)[13], and have never been prospectively validated in large cohorts. 1 
Moreover, their usefulness in clinical practice has been recently largely questioned[16,17]. Among 2 
224 ST-segment elevation myocardial infarction (STEMI) patients who underwent retrospective 3 
assessment, none met the major criteria proposed by Liu. However, the presence of PR-displacement 4 
in any leads was common (31% of cases) and independently predicted a 30-day, as well as 1-year 5 
mortality (adjusted odds ratio 6.22; 95% confidence interval [CI] 2.33-18.64)[17]. In the setting of a 6 
case-control sub-analysis of the APEX-AMI,  which included 630 patients with or without new-onset 7 
atrial fibrillation, the presence of abnormal P-wave morphology was significantly associated with new 8 
atrial fibrillation (adjusted odds ratio, 1.68; 95% CI 1.03-2.73), and was independently associated with 9 
mortality at 90-day follow-up in the overall (adjusted hazard rate, 1.90; 95% CI 1.04 to 3.46) and new-10 
onset atrial fibrillation (adjusted hazard rate, 2.43; 95% CI 1.22 to 4.84) cohorts. The current evidence 11 
is mainly derived from retrospective and modestly sized STEMI studies. The evidence on patients 12 
with NSTE-ACS remains very limited, and few studies have assessed P-wave morphology in 13 
association with angiographic data in order to corroborate the occurrence of atrial infarction[12,43]. In 14 
addition, none of the previous studies investigated the possible differential impact of measuring PR-15 
displacement at atrial J-point versus maximum point of deviation, the clinical meaning of PR-segment 16 
slope (horizontal, slight, marked down- and up-slope), and concordance/discordance between P-wave 17 
and PR-deviation polarity, or the prognostic implications of P-wave/PR-segment abnormalities 18 
resolution (or persistence) after PCI. Moreover, prior studies focused on P-wave morphology either 19 
mainly or exclusively in isolation from other ECG changes. Therefore, it remains unclear whether P-20 
wave/PR-segment morphology truly predicts outcomes, including mortality, independently from other 21 
concomitant ECG changes and/or extent of ventricular ischemia. Finally, no study has assessed the 22 
association between ECG pattern of atrial infarction and subsequent stroke risk. The supplementary 23 
appendix provides detailed descriptions of how ECG metrics are centrally assessed.  24 
 25 
The prognostic role of Q-wave regression and the issue of a standardized definition 26 
The presence of Q-waves in patients with ACS has more than a mere descriptive or 27 
electrocardiographic meaning, as it entails relevant information regarding the pathophysiology, 28 
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anatomy, and prognosis[44–46]. Although over the last decades, the diagnostic importance of Q-wave 1 
infarction has been overshadowed by a more recent definition centered on ST-segment deviation[47], 2 
this entity still to date has a remarkable value[7,48,49]. Approximately 30% of ACS patients have new 3 
pathological Q-waves as marker for advanced stages in infarct evolution, more extended and less 4 
reversible injury, as well as a  worse prognosis[7,45,46,49–52]. A variety of definitions for 5 
pathological Q-waves have been previously published (Table 1)[53–58]. Earlier studies defined a Q-6 
wave as pathological if lasting more than 40 ms with an amplitude of more than 25% of the 7 
corresponding R-wave[53,54]. Over the years, the criteria for pathological Q-waves have been 8 
redefined from classic[53,54] to the most recent definition reported in the 2018 Universal Definition 9 
of MI[47]. The criteria for defining pathological Q-wave (or Q-wave equivalent) have been mainly 10 
derived from patients without acute myocardial ischemia[59,60], thus raising potential issues 11 
regarding the appropriateness of their use in ACS. Moreover, considering the relevant differences 12 
among various criteria, it is not uncommon that Q-waves can be defined as pathological by some 13 
definitions, but not by others. As a consequence, patients can be diagnosed as having (or not) 14 
pathological Q-waves based on which definition is used. Several studies compared previously 15 
published criteria to assess their diagnostic and prognostic implications[61–64]. In a large population 16 
study, Q-waves classification based on the Third Universal Definition of MI did not provide 17 
advantages compared to simple ≥40 ms Q-wave criteria with respect to predicting the risk of 18 
cardiovascular death[63]. In 184 STEMI patients treated with primary PCI, Delewi et al. showed that, 19 
among previously proposed Q-wave definitions, classic criteria for Q-wave had the best correlation 20 
with infarct size as determined by cardiac magnetic resonance[62]. In agreement with other 21 
studies[61,65], these findings suggested high specificity (due to a more strict definition) of classic 22 
criteria as opposed to high false positivity of the more recently proposed criteria for detecting 23 
myocardial injury. A drawback in using overly stringent (and less sensitive) criteria means risking 24 
missing out on clinically relevant information; this is especially so in high-risk patients such as those 25 
with ACS. To date, it is largely unclear, although potentially relevant for clinical practice, whether the 26 
classic or more recent Q-wave criteria better predict clinical outcomes in ACS patients, pointing to the 27 
importance of a contemporary reappraisal of this topic. 28 
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Another matter of controversy is whether dynamic Q-wave changes between pre and post-treatment 1 
ECGs (either new development, worsening, or regression) can predict clinical outcomes[48,62,66,67]. 2 
Q-wave appearance can be transient and due to ischemic conduction delay in vital (electrically 3 
inactive) myocardium rather than irreversible necrosis; thus, their resolution might be a marker of 4 
effective myocardial salvage in patients who are readily reperfused[67–69]. On the other hand, their 5 
appearance after PCI and/or persistence at discharge might imply more severe ischemic injury and 6 
failed reperfusion. As compared with Q-wave persistence, Q-wave regression has been associated with 7 
better myocardial recovery and larger improvement in left ventricular function at cardiac magnetic 8 
resonance and perfusion SPECT, suggesting potential clinical relevance[62,70]. However, results from 9 
imaging and clinical studies actually diverge. The HORIZONS-AMI, evaluating 1,084 STEMI 10 
patients with Q-waves on their presenting ECG, failed to show any significant differences in terms of 11 
cardiac death (5.1 vs. 9.2%; P=0.10) and all-cause death (2.9% vs. 5.6%; P=0.052), between patients 12 
with resolved versus persistent Q-waves at discharge, even though the percentage of events was 13 
numerically halved in the former[7]. To note in this study, the definition of pathological Q-waves was 14 
based on Selvester QRS criteria[7]. Thus, the contemporary prognostic value of Q-wave development, 15 
worsening, or regression after treatment, as well as their definition, remains a topic worth investigating 16 
further. 17 
 18 
ST-deviation and resolution in STEMI and NSTE-ACS settings 19 
Due to its high specificity, low cost, and near-universal availability, ST-segment deviation plays a 20 
central role in the management of patients with suspected ACS[71–74]. The mechanism of regional 21 
ST-deviation after occlusion of a coronary artery has been widely studied and is related to regional 22 
loss of function of ion channels generating electrical gradients[75]. The characteristic changes of ST-23 
segments on the standard twelve-lead ECG during ischemia and after reperfusion (either by 24 
thrombolysis or PCI) have made the analysis of ST an indispensable tool, not only to diagnose ACS 25 
but also to localize the occluded coronary artery, detect the site of occlusion (proximal versus distal), 26 
predict outcomes, and evaluate treatment success/failure[4,23,25,76,77]. Moreover, the use of 27 
additional right precordial leads (especially V4R) is of valid help in diagnosing right ventricular 28 
9 
 
involvement and carries relevant implications in clinical decision-making[78,79]. Since right 1 
precordial leads were not recorded for the purpose of the MATRIX trial, we will investigate the 2 
usefulness of standard 12-lead ECGs in identifying the site of culprit lesion in a large and 3 
contemporary cohort of patients who underwent routine coronary angiography.  4 
The clinical relevance of ischemic ST-segment changes has been extensively investigated in the 5 
STEMI population[6,76,80–85]. The early resolution of ST-deviation (ST-segment recovery) as well 6 
as post-treatment residual ST-deviation have been repeatedly shown to carry independent prognostic 7 
implications after infarction, well beyond post-treatment angiographic data[6,76,80–84,86,87]. 8 
Whether access site and pharmacologic regimen can impact on ST-segment recovery remains unclear. 9 
Radial access has been shown to reduce ischemic and bleeding events and mortality as compared to 10 
femoral access[33,34,88–91]. In addition, some authors advocated increasing time to reperfusion by 11 
radial access due to technical challenges and higher crossover rates, especially in the case of STEMI 12 
and non-experienced operators[92,93]. Actually, no large study compared the impact of radial versus 13 
femoral access on myocardial reperfusion based on ECGs analysis. Previous studies reported a 14 
comparable effect of bivalirudin and unfractionated heparin plus GPI on ST-resolution and residual 15 
ST-deviation after PCI[81,94,95]. However, an adequately powered comparison of bivalirudin versus 16 
heparin (with or without GPI) on ECG measures of myocardial perfusion had not been previously 17 
published. Moreover, no large study prospectively evaluated the possible differential impact of 18 
different bivalirudin regimens (either full versus low dose or prolonged versus short-term infusion) on 19 
ST-resolution. Among different studies, numerous measurement methods have been proposed, mainly 20 
differing for the number of ECGs (index and post-treatment[96], or post-treatment only), number of 21 
leads (all leads, selected leads according to MI location, or single worst lead), ST-deviation direction 22 
(ST-elevation only, or combined ST-elevation and depression), quantification of ST-recovery (% of 23 
resolution, absolute resolution, or residual ST-deviation), speed of ST-recovery, and cut-off/s 24 
used[6,76,80–84,97]. In this context, comparative studies aiming at establishing the gold standard 25 
method for calculating ST-segment resolution/persistence provided controversial results. Buller[6] and 26 
Verouden[97] and colleagues came up with conflicting conclusions, reporting that residual ST-27 
elevation measured in the most affected lead on post-treatment ECG only[6] and the sum of ST-28 
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deviation resolution (at a 50% cut-off) on pre and post-treatment ECG[97] were the best independent 1 
predictor of mortality, respectively. Although several hypotheses have been put forth to explain 2 
differences in results (i.e., timing for ECGs recording, randomized versus real-world study, statistical 3 
approach), the puzzle remains unsolved. Further investigation of which ST-recovery measurement 4 
methods can better predict outcomes in a contemporary setting of STEMI treated by default primary 5 
PCI and potent P2Y12 inhibitors, and with limited use of GPI, is actually of critical importance. 6 
Finally, whether combining additional signs of ischemia resolution (i.e., Q-wave disappearance, QRS 7 
and T-peak to T-end interval narrowing) might implement the ability to predict successful reperfusion 8 
and outcomes remains yet to be determined.  9 
The presence of ST-depression on admission ECG among NSTE-ACS patients is currently used to 10 
identify patients at higher risk for events, and who may benefit from an early invasive strategy[72,98–11 
100]. Data from large trials showed the relevant predictive role of ST-depression on admission for 12 
death and recurrent MI[101–103], which suggested a positive correlation between the severity of ST-13 
depression and outcomes[101–103]. However, discordant data have also been reported. In the Global 14 
Registry of Acute Coronary Events (GRACE) and Canadian ACS Registry registries[104,105], the 15 
quantitative assessment of ST-depression failed to show an incremental predictive value for clinical 16 
outcomes as compared to the simple qualitative evaluation (presence or absence) of ST-17 
depression[104,105]. Also, the value of post-treatment ST-depression resolution in patients with 18 
NSTE-ACS remains under-investigated and less well defined by specific criteria compared with 19 
STEMI[106,107], and clear cut-off value, as well as the point for the correct assessment (J-point vs. 60 20 
ms after J point), remain unclear. Thus, considering current limitations, the prognostic role of ST-21 
segment deviation and resolution in the NSTE-ACS patients should be better clarified. 22 
 23 
Role of ECG in identifying culprit lesion location and patency among ACS patients 24 
Numerous ECG criteria/algorithms aimed at predicting culprit lesion location (and their potential 25 
prognostic implications) have been previously published[18–22,108–111] and reviewed[4,5,112,113]. 26 
However, in a recent validation cohort study, their performance was poor, suggesting a lack of 27 
generalizability in current practice[114]. Prior studies attempting to correlate ECG patterns with the 28 
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culprit lesions location entail several limitations. First, they often implemented a retrospective design 1 
and the inclusion of a modest number of patients (often less than a hundred) that were additionally 2 
grouped per vessel (i.e., RCA versus LCX) or site (proximal versus distal) of occlusion[4,5,18,23,25]. 3 
Moreover, their execution largely predated the modern primary PCI era where immediate angiography 4 
provides greater reliability for culprit lesion identification[23,25]. Finally, previous analyses mainly 5 
focused on selected ACS populations, such as those with single-vessel disease and inferior or anterior 6 
locations, excluding those with multi-vessel disease [18–20, 23,25,108,109]. 7 
While most analyses focused so far on the degree of ST-deviation for the identification of culprit 8 
lesion location, no large study clarified whether measuring it at the J-point or more downstream (i.e., 9 
20, 60 or 80 ms after the J-point), may impact ECG prediction compatibility[115,116]. Moreover, 10 
dynamic changes in the QRS complexes, ST-segments, and T-waves often occur during culprit 11 
occlusion. Whether the combination of multiple ECG parameters (i.e., QRS duration and morphology, 12 
axis orientation, T-wave characteristics) in a more comprehensive ECG algorithm/score can improve 13 
the reliability of currently used criteria for localizing culprit remains to be determined. Finally, no 14 
prior study has assessed the capability of ECG in identifying culprit lesion patency and conversely its 15 
role on ECG alterations and outcomes in STEMI patients.  16 
 17 
Total occlusion of the culprit artery in NSTE-ACS 18 
The presence of a total occlusion of culprit coronary artery is usually associated with ST-elevation on 19 
ECG in ACS patients, and requires immediate coronary angiography and revascularization. However, 20 
a considerable proportion of acute coronary occlusion may be missed if the ECG is assessed only for 21 
ST-elevation in contiguous leads, fulfilling diagnostic criteria for STEMI[26,28,117–119]. Indeed, a 22 
subset of NSTE-ACS patients (approximating at ¼ of cases) presents a total culprit vessel occlusion  23 
(Thrombolysis in Myocardial Infarction [TIMI] flow grade 0/1) at coronary angiography, without any 24 
evidence of classic STEMI pattern[26–28,120–122]. In more than 70% of these cases, either the right 25 
coronary or left circumflex artery are involved, with a predominant infero-lateral and posterior infarct 26 
distribution[26–28,121]. As proof of concept, occlusion of the left circumflex is underreported in 27 
studies recruiting STEMI (only 15% of cases)[26], a possible consequence of the silent nature of 28 
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perfused territory on standard twelve-lead ECG[26,27]. These patients with ‘missed STEMI’ and total 1 
occlusion of the culprit artery almost systematically received delayed invasive treatment, being 2 
referred to the catheterization laboratory 24-48 hours after initial presentation[26–28,123]. This point 3 
poses relevant concerns due to the established detrimental impact of culprit occlusion on outcomes and 4 
potential benefit from earlier reperfusion. The TRITON–TIMI 38 (Trial to Assess Improvement in 5 
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial 6 
Infarction 38) enrolled 13,608 ACS patients, of whom 1,198 or 8.8% presented with anterior ST-7 
depression[27]. Of those, 314 or 26.2% had an occluded culprit at coronary angiography (performed at 8 
a median time from ECG of 29.4 h), with a left circumflex involvement in half of the cases. At 30-day 9 
follow-up, the rate of death and MI was significantly higher among patients with an occluded artery as 10 
compared with those with a patent culprit artery, suggesting the relevant prognostic value of this factor 11 
and the inadequate management of these patients[27]. Confirming these data, a recent meta-analysis of 12 
40,777 subjects estimated that NSTE-ACS patients with total occlusion of culprit artery are at a higher 13 
risk of both major adverse cardiac events and all-cause mortality at short (risk ratio [RR] 1.41; CI 14 
1.17-1.70; P = 0.0003 and RR 1.67; CI 1.31-2.13; P < 0.0001, respectively) and long-term (RR 1.32; 15 
CI 1.11-1.56; P = 0.001 and RR 1.42; CI 1.08-1.86; P = 0.01, respectively) follow-up[28]. 16 
Therefore, patients presenting with NSTE-ACS with an occluded culprit vessel on coronary 17 
angiography represent a high-risk subset whose identification remains challenging, and for whom 18 
current guidelines do not provide specific recommendations[72,98]. Although several ECG criteria, 19 
based on the magnitude and location of ST-depression, pathological Q-waves, and R/S ratio in leads 20 
V1-V2 have been proposed, results from previous studies conflict and are not validated in the large 21 
NSTE-ACS population, making their practical values unclear[26,28,117,121,124–126]. The 22 
recognition of subtle ECG findings suggesting  the presence and location of ongoing ischemia and 23 
possible coronary occlusion (including a distinct ST-elevation in aVR or minor [non-diagnostic] ST-24 
elevation in other leads, T-wave width/morphology following ST-depression [i.e., de Winter’s sign], 25 
U-wave polarity [positive vs. negative]) may be of value in patients presenting with NSTE-ACS.  26 
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To date, implementing the correct and timely identification of acute coronary occlusion in the NSTE-1 
ACS setting by specific ECG patterns/algorithms could be crucial to facilitate earlier revascularization 2 
(following a “STEMI-like pathway”) and improve patients’ prognosis in contemporary practice. 3 
 4 
The prognostic role of T-wave morphologies and indices in ACS 5 
Although numerous studies have so far investigated and reviewed the role of T-wave abnormalities in 6 
ACS[3,11], their prognostic significance remains a matter of contention[127–129]. In large ACS 7 
studies, patients with isolated T-wave inversion (TWI) had similar cardiovascular outcomes and extent 8 
of coronary lesions compared with those presenting normal ECG[128,130]. In line with these reports, 9 
a recent sub-analysis of GRACE and Canadian ACS registries evaluating 7,201 NSTE-ACS 10 
patients[131], TWI was a marker of high-risk profile (i.e., elderly, multiple cardiovascular risk factors) 11 
but not an independent predictor of adverse outcomes[131]. On the other hand, other studies identified 12 
specific T-wave abnormalities, as defined by Wellens[132] and de Winter[133], which are associated 13 
with critical stenosis/occlusion of the proximal LAD and carry adverse prognostic implications if not 14 
promptly invasively managed[127,132]. Moreover, Jacobsen et al. demonstrated that patients with 15 
diffuse T-wave abnormalities had significantly worse outcomes[134] and benefited from an early 16 
invasive as compared with a conservative strategy[135]. Methodological issues, low number of 17 
patients undergoing coronary angiography, and considerable heterogeneity among populations might 18 
have partially obscured the potential adverse prognostic impact of T-wave abnormalities in previous 19 
studies. Further investigations regarding different aspects of T-wave abnormalities, including type, 20 
location (anterior vs. non-anterior), extent (number of leads), and dynamics (pre and post-21 
revascularization changes) are necessary to shed light on this persistently ambiguous sign. 22 
An additional T-wave-derived parameter, the T-peak to T-end interval (Tp-e), has been recently 23 
proposed as a potential outcomes predictor in patients with ACS. Tp-e prolongation marks an 24 
increased ventricular repolarization dispersion, the final substrate for ventricular arrhythmias and 25 
sudden cardiac death in ischemic heart disease[136]. Erikssen et al.[136], evaluating 1,384 ACS 26 
patients referred to coronary angiography, showing that prolonged Tp-e (relative risk 1.5, 95% CI 1.3 27 
to 1.7) and heart rate-corrected Tp-e (relative risk 1.6; 95% CI 1.4 to 1.9) were strongly associated 28 
14 
 
with an increased risk of death, particularly for fatal arrhythmias. Initial evidence warrants further 1 
investigations to elucidate the relationship between prolonged Tp-e with clinical, angiographic, and 2 
outcome data in the whole ACS population, also to clarify which measurement method (tangent versus 3 
tail method) should be used, and which is the prognostic impact of Tp-e interval changes from 4 
admission to serial follow-up ECGs. 5 
 6 
Materials and methods 7 
Study design and population 8 
Between October 11, 2011, and November 7, 2014, the MATRIX trial (NCT01433627) enrolled 8,404 9 
patients with an ACS (both STEMI and NSTE-ACS) for whom invasive management was 10 
planned[32–34]. Detailed rationale, design, and results have been previously reported[32–34,137]. Per 11 
study protocol, standard twelve-lead ECGs (paper speed of 25 mm/s, calibrated at 1 mm = 0.1 mV) 12 
were recorded in all patients, and classified as: (a) index ECG, before coronary angiography (at the 13 
time of qualification for the inclusion in the trial); (b) post-procedural ECG, after the index coronary 14 
angiography and/or PCI; (c) predischarge ECG, during the hospital stay or at the time of discharge. 15 
The ECG-MATRIX is a predefined sub-study of the MATRIX aimed at investigating the role of pre 16 
and post-procedural ECG features to predict outcomes as well as angiographic findings in ACS 17 
patients receiving invasive management. Moreover, the study sought to evaluate the impact of the 18 
access site and/or pharmacological regimens on ECG patterns after PCI to gain further insight into the 19 
comparative effectiveness on ECG parameters of procedural success of the two randomly allocated 20 
intervention. This sub-study is being executed in accordance to previously proposed criteria for 21 
conducting ECG sub-study which is nested within prospective trials in patients with coronary artery 22 
disease[35]. Eligible patients for the sub-study were all participants in the trial. Since there was no 23 
predefined fee for participating in the ECG-MATRIX sub-study, each site was originally invited to 24 
participate on a voluntary basis. A total of 39 centers recruiting 6,764 patients declared their interest in 25 
participating. After excluding patients in whom ECGs were not available for central analysis, 4,516 26 
patients (2,212 or 49% STEMI, and 2,304 or 51% NSTE-ACS), which accounts for 53.7% of the 27 
15 
 
study population, of whom 4,022 patients have matched pre and post-treatment ECGs (1,999 or 49.7% 1 
STEMI, and 2,023 or 50.3% NSTE-ACS), are eligible for the study.  2 
From January to August 2018, all collected ECGs were anonymously catalogued, assessed for quality, 3 
and digitized for central analysis with a final sampling rate of 500 samples/sec, in accordance with 4 
current standards for adult ECGs[138]. The final version of the study design and methods were 5 
defined in September 2018. ECG analysis started in October 2018 and is projected to reach completion 6 
by Q2 2020. As per June 2, 2019, matched pre and post-treatment ECGs from 644 patients have been 7 
analyzed. 8 
 9 
Methods for ECG analysis 10 
Central ECG analysis is performed at the Department of Cardiology, Inselspital, University of Bern, 11 
Switzerland, by 13 fully trained cardiologists who are blinded to the original randomization scheme 12 
and clinical outcomes (Table 2). To avoid inter-reader variability, all matched (index and post-13 
treatment) ECGs for each individual patient are measured by a single assessor. The average time for 14 
central reading of a single ECG approximates to 45 minutes. All measurements are performed in a 15 
computer environment using professional computer software (EP Calipers®, 16 
www.epstudiossoftware.com/about-ep-calipers/). The software allows manual (operator-interactive) 17 
measurements of digital ECG images (in high-resolution) using electronic calipers set manually by the 18 
operators. This method has been selected for the present ECG sub-study, as it previously showed high 19 
accuracy and reproducibility, limiting operator variability, and allowing to work on a large number of 20 
ECG recordings easily[139,140].  21 
 22 
Inter-reader agreement assessment 23 
Previous studies underscored the importance of minimizing inter-reader differences in ECG analysis 24 
and interpretation within and across ECG core laboratories, considering the relevant clinical 25 
implications that this entails [141–143]. Moreover, inter-reader agreement analysis for ECG metrics 26 
such as P-wave or PR-deviation measurements is rarely reported in the literature. Pearson correlation 27 
and Bland-Altman plot analysis between the reference reader and reader 1 for PR-segment depression 28 
16 
 
(at J-point and maximum point of deviation) are shown in figure 2, and detailed methods and results 1 
for all readers and metrics are shown in the supplementary appendix. Our findings demonstrate a 2 
high inter-reader agreement among readers in all the investigated ECG metrics (in line with previous 3 
results reported in the literature)[141–143] and support the accuracy of ECG analysis. 4 
ECG-MATRIX pre-specified sub-analyses 5 
For the purpose of this study, the following sub-analyses are pre-specified: 6 
- atrial infarction sub-analysis, to assess the prognostic significance of ECG signs suggestive for 7 
atrial infarction on admission and their resolution after PCI; 8 
- Q-wave sub-analysis, to compare the prognostic impact of pathological Q-waves defined 9 
according to the 2018 Universal MI definition with the previously reported definitions, and to 10 
assess the prognostic value of Q-wave resolution after PCI; 11 
- ECG value for predicting coronary flow and anatomical characteristics in STEMI patients;  12 
- ECG value for predicting culprit vessel occlusion on coronary angiography in NSTE-ACS; 13 
- T-wave pattern sub-analysis, to evaluate the prognostic relevance of T-wave metrics, and their 14 
dynamic changes on serial ECGs. 15 
 16 
The complete list of pre-specified sub-analyses is reported in the supplementary appendix. 17 
 18 
Conclusions 19 
The MATRIX trial was designed to test the impact of bleeding avoidance strategies, radial access and 20 
bivalirudin in comparison with femoral access and unfractionated heparin with optional GPI 21 
respectively, on ischemic and bleeding outcomes in patients with ACS undergoing invasive 22 
management.  23 
This will represent the largest contemporary study analyzing the role of ECG for the diagnosis and risk 24 
stratification of ACS patients with or without ST-segment deviation, concurrently exploring atrial and 25 
ventricular ischemia on matched pre and post-treatment ECGs. The ECG-MATRIX will attempt to 26 
answer some outstanding questions regarding specific ECG parameters in the diagnosis and 27 
17 
 
management of ACS patients as well as reassessing the role of known ECG metrics in contemporary 1 
practice consisting of early invasive management. 2 
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Figure legends 1 
Figure 1. Diagnostic criteria for atrial infarction proposed by Liu et al. [13], Hellerstein [15], and 2 
Sivertssen et al. [41].  3 
Figure 2. Pearson correlation and Bland-Altman plot analysis for PR-segment depression from the 4 


























Table 1. Multiple definitions of pathological Q-waves classification 1 
 
Classic criteria [53,54,144] Q-wave with a duration ≥40 ms and/or a depth ≥25% of the R-wave 
in the same lead or the presence of a Q-wave equivalent  
TIMI criteria [55] Q-wave ≥30 ms in 2 contiguous leads, any Q- or R-wave ≤10 ms and 
≤1 mm in lead V2, and R-wave ≥40 ms in V1  
Selvester QRS Scoring System 
[56] 
Q-wave duration ≥30 ms in leads I, II, aVL, aVF, V5, V6, or ≥20 ms 
in V4, or any Q-wave in V1, V2, V3 
R-wave duration ≥40 ms in V1, or ≥50 ms in V2, or ≤30 ms in V3 
R/Q ratio ≤1 in leads I, aVL, aVF 
R/S ratio ≥ 1 in lead V1 
R/S ratio ≥ 1.5 in lead V2 
R/Q or R/S ratio ≤ 0.5 in lead V4 
R/Q or R/S ratio ≤ 1 in leads V5, V6 
Selvester QRS Screening 
Criteria [59,60] 
Q-wave ≥ 30 ms in aVF 
R-wave ≤ 1 mm and/or ≤ 10 ms in V2 
R-wave ≥ 40 ms in V1 
Additional criteria: 
Q-wave ≥ 40 ms in leads I and aVL 
Q-wave ≥ 40 ms in ≥ 2 leads of V4, V5, or V6 
Any Q-wave in V2  
Minnesota Code Manual [57] Major Q-waves: Q-wave ≥ 50 ms in any leads; Q-wave ≥ 40 ms in 
any leads other than aVF and III; Q-wave ≥ 30 ms with R/Q < 3 in 
leads V2-V6, I, or II; QS-wave in lead V4 or V5; or an initial R 
wave in leads V1–V5 and flag QS in the next leads V2–V6 
Moderate Q-waves: Q-wave ≥ 40 ms in lead aVF or III; Q wave ≥ 30 
ms V2-V6, I, or II; Q-wave ≥ 20 msec and R/Q < 3 in leads V2-V6, 
I, or II; or QS-wave in leads V3, I, or II 
Minor Q-waves: Q-wave ≥ 30 ms in leads aVL, aVF, or III; Q-wave 
≥ 20 ms and R/Q < 5 in leads V2-V6, I, or II; or QS in leads aVF, 
III, or V2 
2000 ESC/ACC Consensus 
[58] 
Any Q-wave in leads V1 through V3, Q-wave ≥30 ms in leads I, II 
aVL, aVF, V4, V5, V6 
The Q-wave changes must be present in any two contiguous leads, 
and be ≥1 mm in depth  
2018 Fourth Universal 
Definition of MI [47] 
Any Q-wave in leads V2–V3 ≥20 ms or QS complex in leads V2-V3 
Q-wave ≥30 ms and ≥1 mm deep or QS complex in leads I, II, aVL, 
aVF or V4-V6 in any two leads of a contiguous lead grouping (I, 
aVL, V6; V4–V6; II, III, and aVF; V7-V9) 
R-wave ≥40 ms in V1-V2 and R/S ≥1 with a concordant positive T-










Table 2. ECG metrics and patterns analyzed in the ECG-MATRIX 1 
Heart rhythm  - Heart rate 
- Rhythm definition 
- Rhythm disturbance (supra-ventricular and ventricular arrhythmias) 
- Premature ectopic beats (atrial and ventricular) 
Frontal plane 
QRS axis 
- Normal axis orientation 
- Left or right axis deviation  
Atrial 
depolarization  
- P-wave voltage  
- P-wave duration  
- P-wave dispersion  
- P-wave time-to-peak (atrial intrinsicoid deflection) 
- P-peak to P-end interval  
- P-wave peak-to-end interval 
- P-wave morphology (i.e., irregular, M- / W-shaped)  
- P-wave terminal force in V1 
- Left atrial enlargement 
- Right atrial enlargement 
- Interatrial block 
Atrial 
repolarization 
- PR-deviation at atrial J-point (elevation and/or depression)  
- Maximum PR-deviation (elevation and/or depression) 
- ∑ PR-deviation at atrial J-point (elevation and/or depression) 
- ∑ Maximum PR-deviation (elevation and/or depression)  
- PR-deviation resolution at atrial J-point (elevation and/or depression)  
- Maximum PR-deviation resolution (elevation and/or depression) 
- PR-segment deviation slope (flat, slightly/markedly down-sloping or up-
sloping)  
- P-wave / PR-segment junction shape distinguishing a smooth-angled versus a 
sharp-angled 
- P-wave polarity / PR-deviation concordance (or discordance) 
Atrioventricul
ar conduction 
- PR-interval duration 
- Time relation between P-wave / QRS complex 
- Atrioventricular block  
- Wolf-Parkinson-White pattern 
Ventricular 
depolarization 
- Q-, R-, S-, R’-, S’- (individual) waves voltage 
- Q-, R-, S-, R’-, S’- (individual) waves duration  
- R-wave time-to-peak (ventricular intrinsicoid deflection);  
- Peak-to-peak QRS complex amplitude 
- Net QRS complex deflection 
- QRS complex duration 
- QRS complex dispersion 
- Complete/incomplete right/left bundle branch block 
- Left anterior/posterior fascicular block 
- Bifascicular block 
Ventricular 
repolarization 
- ST-segment deviation at J-point (elevation and/or depression) 
- ST-segment deviation 60 ms after the J-point (elevation and/or depression) 
- ∑ ST-segment deviation at J-point (elevation and/or depression) 
- ∑ ST-segment deviation 60 ms after the J-point (elevation and/or depression) 
- ST-segment resolution at J-point (elevation and/or depression) 
- ST-segment resolution 60 ms after the J-point (elevation and/or depression) 
- Non-persistent ST-segment elevation 
- Dynamic ST-segment shifts 
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- T-wave amplitude 
- Peak-to-peak T-wave amplitude 
- Net T-wave deflection 
- T-wave duration 
- T-wave morphology (i.e., biphasic, hyper-acute) 
- T-wave time-to-peak (T-wave intrinsicoid deflection) 
- Tp-e interval with tail method (with and without  Bazett’s correction) 
- Tp-e interval with tangent method (with and without  Bazett’s correction) 
- Tp-e interval dispersion 
- JT-interval with tail method (with and without Bazett’s correction) 
- JT-interval with tangent method (with and without Bazett’s correction) 
- JT-interval dispersion 
- JT-interval prolongation index  
- QT-interval with tail method (with and without Bazett’s correction) 
- QT-interval with tangent method (with and without Bazett’s correction) 
- QT-interval dispersion 






- Wellens’ pattern 
- De Winter’s pattern 
- Sgarbossa’s criteria for left bundle branch block 
- Smiths’ criteria for left bundle branch block 
- Anderson-Wilkins acuteness score 
- Left ventricular hypertrophy 
- Right ventricular hypertrophy  
- Index of Cardiac Electrophysiological Balance (iCEB) 
- ECG-based Regional Restitution Instability Index (R2I2) 
- Mechanical systole duration by Waller's formula 
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